The occurrence of colon cancer in parallel with GLP1-RAs use, compared to pancreatic and other glands’ cancer (especially thyroid), seems to be very low and, in any case, these treatments seem to reduce the possibility of cancer cell progression in subjects with a pre-existing cancerous lesion. The gene discussed is GCG; the disease is malignant colon neoplasm.